A Study of BL-B01D1 + SI-B003 in Patients With Unresectable, Locally Advanced or Recurrent Metastatic HER2-negative Breast Cancer
Condition: Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Interventions: Drug: BL-B01D1; Drug: SI-B003 Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
Conditions: Breast Cancer; Metastatic Breast Cancer Intervention: Drug: Trastuzumab-Deruxtecan (T-DXd) Sponsors: MedSIR; Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Condition: Gastroesophageal Adenocarcinoma Interventions: Drug: Paclitaxel; Drug: Ramucirumab; Drug: Zanidatamab Sponsors: Canadian Cancer Trials Group; Jazz Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study of BL-B01D1 + SI-B003 in Patients With Unresectable, Locally Advanced or Recurrent Metastatic HER2-negative Breast Cancer
Condition: Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Interventions: Drug: BL-B01D1; Drug: SI-B003 Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Condition: Gastroesophageal Adenocarcinoma Interventions: Drug: Paclitaxel; Drug: Ramucirumab; Drug: Zanidatamab Sponsors: Canadian Cancer Trials Group; Jazz Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study of BL-B01D1 + SI-B003 in Patients With Unresectable, Locally Advanced or Recurrent Metastatic HER2-negative Breast Cancer
Condition: Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Interventions: Drug: BL-B01D1; Drug: SI-B003 Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
Conditions: Breast Cancer; Metastatic Breast Cancer Intervention: Drug: Trastuzumab-Deruxtecan (T-DXd) Sponsors: MedSIR; Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Condition: Gastroesophageal Adenocarcinoma Interventions: Drug: Paclitaxel; Drug: Ramucirumab; Drug: Zanidatamab Sponsors: Canadian Cancer Trials Group; Jazz Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study of BL-B01D1 + SI-B003 in Patients With Unresectable, Locally Advanced or Recurrent Metastatic HER2-negative Breast Cancer
Condition: Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Interventions: Drug: BL-B01D1; Drug: SI-B003 Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
Conditions: Breast Cancer; Metastatic Breast Cancer Intervention: Drug: Trastuzumab-Deruxtecan (T-DXd) Sponsors: MedSIR; Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma Interventions: Drug: Cyclophosphamide; Drug: Docetaxel; Other: Medical Chart Review; Other: Questionnaire Administration Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
